Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-3106 +/- INO-9012 in HPV6-associated Aerodigestive Lesions
NCT02241369Phase 1Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- May 2014
- Primary completion
- Sep 2018
- Modality
- Prophylactic Vaccines, DNA Vaccines, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of INO-3106 in recurrent respiratory papillomatosis (RRP), head and neck squamous cell carcinoma (HNSCC) and lung cancer (2 cohorts), sponsored by Inovio Pharmaceuticals, Inc. Primary endpoints: Adverse events measured and graded in accordance with CTCAE v4.03 up to 6 months and Injection site reactions including skin erythema, induration pain and tenderness up to 15 weeks. Started May 2014; status: completed.
02
Drugs
INO-3106
03
Conditions
recurrent respiratory papillomatosis (RRP)head and neck squamous cell carcinoma (HNSCC)lung cancer
Beyond the preview
Go deeper on NCT02241369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241369.